## User

This is the beginning of an individual meeting with Medicinal Chemist to discuss your research project.

Here is context for this meeting:

[begin context 1]

ExperimentPeptideSynthesis[OligomerModels]⟹Protocol

uses a oligomer OligomerModels to create a Peptide Synthesis Protocol and associated synthesis cycles methods.





Peptide synthesis is the production of peptides, where multiple amino acids are linked via amide bonds. Peptides are chemically synthesized by the condensation reaction of the carboxyl group of one amino acid to the amino group of another. This can be achieved with classical solution phase synthesis or solid phase synthesis, which is used in this experiment. In solid phase synthesis, amino acids are covalently bound to a solid support material and synthesised step-by-step in a single reaction vessel utilising selective protecting group chemistry. Peptides are attached to the solid support from their C terminus. Peptide synthesis occurs by coupling the carboxyl group of the incoming amino acid to the N-terminus of the growing peptide chain. This C-to-N synthesis is opposite from protein biosynthesis, during which the N-terminus of the incoming amino acid is linked to the C-terminus of the protein chain (N-to-C). The benefit of the solid support is the isolation of synthesis sites, making interference between growing chains impossible. The use of protecting groups is essential to avoid undesirable side reactions during this process. The most common protecting groups for amino groups used in peptide synthesis are 9-fluorenylmethyloxycarbonyl group (Fmoc), which is used in this experiment, and t-butyloxycarbonyl (Boc). Peptide synthesis allows the production of specific sequences facilitating the study protein function and the development of antibiotic drugs, antibodies and peptide biomaterials. ExperimentTotalProteinQuantification, ExperimentMassSpectrometry and ExperimentHPLC with fraction analysis can be run on the results of this experiment to measure the yield, verify the molecular weight and measure percent purity of the product.



Experimental Principles

Figure 1.1: Procedural overview of a PeptideSynthesis experiment. Step 1: Define the amino acid sequence to be synthesized, including any modifications, by providing a Model[Sample], a Model[Molecule,Oligomer], a Sequence (Peptide["LysTyrValAlaMet"]), Strand (ToStrand[Peptide["LysTyrValAlaMetTyr"]]) or Structure (ToStructure["LysTyrValAlaMetTyrAla", Polymer -> Peptide]). Step 2: The first monomer is loaded to the resin Step 3: The monomers are then expanded with a cycle of a) removal of the Fmoc protecting group from the resin linker or the last amino acid that is currently on the resin, b) the activation of the monomer and c) the addition on the monomer to the resin or resin with linked strand. Step 4: The peptide is liberated from the resin and side chain protecting groups are removed. Step 5: The peptide is purified by using a solution where the desired peptide strands are insoluble and impurities are soluble. This results in the peptides crashing out of solution. Step 6: The peptide is then resuspended in a resuspension buffer.



Instrumentation

Symphony X

Model[Instrument, PeptideSynthesizer, "id:WNa4ZjRr58Wq"]

Figure 2.1.1: A system of pre-activation vessels (PV), reaction vessels (RV), amino acid bottles, buffers and solutions, waste and collection vessels (CV) connected by channels. The flow in the channels is controlled by Nitrogen gas and the volume of the liquid deliveries are verified with optical sensors.



Experiment Options

Protocol

Instrument

The model or object instrument to be used for this synthesis.

Default Value: Model[Instrument, PeptideSynthesizer, Symphony X]

Pattern Description: An object of type or subtype Model[Instrument, PeptideSynthesizer] or Object[Instrument, PeptideSynthesizer]

Programmatic Pattern: ObjectP[{Model[Instrument, PeptideSynthesizer], Object[Instrument, PeptideSynthesizer]}]

SynthesisStrategy

The type of N-terminal and side chain protecting group scheme used by this synthesis.

Default Value: Fmoc

Pattern Description: Fmoc.

Programmatic Pattern: Fmoc

Scale

The scale at which the oligomers will be synthesized.

Default Value: 5 micromoles

Pattern Description: Greater than or equal to 5 micromoles and less than or equal to 100 micromoles in increments of 2.5 micromoles.

Programmatic Pattern: RangeP[5*Micromole, 100*Micromole, 2.5*Micromole]

Index Matches to: experiment samples

TargetLoading

The desired target loading of the resin to be used for the synthesis.

Default Value: 90 micromoles per gram

Pattern Description: Greater than or equal to 60 micromoles per gram and less than or equal to 200 micromoles per gram.

Programmatic Pattern: Alternatives[RangeP[60*(Micromole/Gram), 200*(Micromole/Gram)]]

Index Matches to: experiment samples

Resin

The model or sample object of resin to be used as the solid support for the synthesis.

Default Value: Automatic

Default Calculation: Will resolve automatically to the undownloaded Resin Model[Sample,"Rink Amide ChemMatrix"] if DownloadResin is set to True. If DownloadResin is set to False, the user is required to specify an appropriate downloaded resin.

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample.

Programmatic Pattern: (ObjectP[{Model[Sample], Object[Sample]}] | _String) | Automatic

Index Matches to: experiment samples

DownloadResin

Indicates if an undownloaded resin will be used and resin download will be performed as the first cycle of the synthesis.

Default Value: True

Pattern Description: True or False.

Programmatic Pattern: BooleanP

Index Matches to: experiment samples

Swelling

SwellSolution

The model or sample object to be used to swell the resin prior to the start of the synthesis or resin download.

Default Value: Automatic

Default Calculation: Automatic will resolve to Model[Sample, "Dichloromethane, Reagent Grade"] if SwellResin has been set to True.

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample or Null.

Programmatic Pattern: ((ObjectP[{Model[Sample], Object[Sample]}] | _String) | Automatic) | Null

SwellResin

Indicates if the resin will be swelled in SwellSolution before the start of a synthesis.

Default Value: True

Pattern Description: True or False.

Programmatic Pattern: BooleanP

Index Matches to: experiment samples

SwellTime

Specifies the amount of time that the resin is swelled for (per cycle).

Default Value: Automatic

Default Calculation: Will automatically resolve to 20 Minutes is SwellResin is set to True.

Pattern Description: Greater than or equal to 0.1 hours and less than or equal to 12 hours or Null.

Programmatic Pattern: (RangeP[0.1*Hour, 12*Hour] | Automatic) | Null

Index Matches to: experiment samples

SwellVolume

Specifies the volume of SwellSolution that the samples will be swelled with.

Default Value: Automatic

Default Calculation: Will automatically resolve to 10 Milliliter if SwellResin is set to True.

Pattern Description: Greater than or equal to 2.5 milliliters and less than or equal to 25 milliliters or Null.

Programmatic Pattern: (RangeP[2.5*Milliliter, 25*Milliliter] | Automatic) | Null

Index Matches to: experiment samples

NumberOfSwellCycles

Specifies the number of the cycles of swelling of the resin before the start of a synthesis.

Default Value: Automatic

Default Calculation: Will automatically resolve to 3 if SwellResin is set to True.

Pattern Description: Greater than 0 in increments of 1 or Null.

Programmatic Pattern: (GreaterP[0, 1] | Automatic) | Null

Index Matches to: experiment samples

Washing

WashSolution

The model or sample object used to wash the resin in between each reagent addition.

Default Value: Model[Sample, Dimethylformamide, Reagent Grade]

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample.

Programmatic Pattern: ObjectP[{Model[Sample], Object[Sample]}] | _String

WashVolume

The volume of WashSolution to be used to wash the resin in between each reagent addition.

Default Value: Automatic

Default Calculation: Will automatically resolve to 4 Milliliter plus an additonal .2 Milliliter for each 1 Micromole of synthesis Scale, rounded up to the nearest .5 Milliliter.

Pattern Description: Greater than or equal to 1 milliliter and less than or equal to 25 milliliters.

Programmatic Pattern: RangeP[1*Milliliter, 25*Milliliter] | Automatic

Index Matches to: experiment samples

Deprotection

DeprotectionSolution

The model or sample object that represents the deprotection solution that will be used to remove protecting groups from the growing strand during the deprotection step of a synthesis or download resin cycle.

Default Value: Automatic

Default Calculation: Will resolve to Model[Sample, StockSolution, "Deprotection Solution (20% piperidine in NMP)"] for Fmoc synthesis and Model[Sample, StockSolution, "95% TFA 5% m-cresol"] for Boc synthesis.

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample.

Programmatic Pattern: (ObjectP[{Model[Sample], Object[Sample]}] | _String) | Automatic

InitialDeprotection

Indicates if an initial deprotection step will be done before the synthesis of the strand begins.

Default Value: False

Default Calculation: The initial deprotection will only occur if DownloadResin is set to True as all other cycles already include a deprotection step prior to their coupling steps.

Pattern Description: True or False.

Programmatic Pattern: BooleanP

Index Matches to: experiment samples

FinalDeprotection

Indicates if a final deprotection step is will be done as part of the last synthesis cycle prior to the start of cleavage or resin storage.

Default Value: True

Pattern Description: True or False.

Programmatic Pattern: BooleanP

Index Matches to: experiment samples

DeprotectionVolume

The volume of DeprotectionSolution added to each reaction vessel during the deprotection step of a synthesis cycle.

Default Value: Automatic

Default Calculation: Automatic will resolve to 3 Milliliter plus an additonal .2 Milliliter for each Micromole of synthesis Scale, rounded up to the nearest .5 Milliliter

Pattern Description: Greater than or equal to 1 milliliter and less than or equal to 25 milliliters.

Programmatic Pattern: RangeP[1*Milliliter, 25*Milliliter] | Automatic

Index Matches to: experiment samples

DeprotectionTime

The amount of time that each reaction vessel is exposed to the deprotection solution during each deprotection step of a synthesis cycle.

Default Value: 20 minutes

Pattern Description: Greater than or equal to 1 minute and less than or equal to 30 minutes.

Programmatic Pattern: RangeP[Minute, 30*Minute]

Index Matches to: experiment samples

NumberOfDeprotections

The number of times that each reaction vessel will be deprotected per deprotection step of a synthesis cycle.

Default Value: 2

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1.

Programmatic Pattern: RangeP[1, 10, 1]

Index Matches to: experiment samples

NumberOfDeprotectionWashes

The number of WashSolution washes each reaction vessel will undergo after the deprotection step of the synthesis cycle.

Default Value: 5

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1.

Programmatic Pattern: RangeP[1, 10, 1]

Index Matches to: experiment samples

Deprotonation

DeprotonationSolution

The model or sample object that represents the DeprotonationSolution that will be used to neutralize the resin prior to the coupling step.

Default Value: Automatic

Default Calculation: Will automatically resolve to Model[Sample, StockSolution, "5% DIEA in DCM"] Deprotonation has been set to True.

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample or Null.

Programmatic Pattern: ((ObjectP[{Model[Sample], Object[Sample]}] | _String) | Automatic) | Null

Deprotonation

Indicates if an optional deprotonation step is performed between the deprotection and capping steps of synthesis cycle.

Default Value: False

Pattern Description: True or False.

Programmatic Pattern: BooleanP

Index Matches to: experiment samples

DeprotonationVolume

The volume of DeprotonationSolution added to each reaction vessel during an optional deprotonation step of a synthesis cycle.

Default Value: Automatic

Default Calculation: Will automatically resolve to 3 Milliliter plus an additonal .2 Milliliter for each 1 Micromole of synthesis Scale, rounded up to the nearest .5 Milliliter.

Pattern Description: Greater than or equal to 1 milliliter and less than or equal to 25 milliliters or Null.

Programmatic Pattern: (RangeP[1*Milliliter, 25*Milliliter] | Automatic) | Null

Index Matches to: experiment samples

DeprotonationTime

The amount of time that each reaction vessel is exposed to the DeprotonationSolution during each deprotonation step of a synthesis cycle.

Default Value: Automatic

Pattern Description: Greater than or equal to 1 minute and less than or equal to 12 hours or Null.

Programmatic Pattern: (RangeP[Minute, 12*Hour] | Automatic) | Null

Index Matches to: experiment samples

NumberOfDeprotonations

The number of repetitions of mixing the resin with the DeprotonationSolution during the deprotonation step of a synthesis cycle.

Default Value: Automatic

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1 or Null.

Programmatic Pattern: (RangeP[1, 10, 1] | Automatic) | Null

Index Matches to: experiment samples

NumberOfDeprotonationWashes

The number of wash solution washes each reaction vessel undergoes after the deprotonation step.

Default Value: Automatic

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1 or Null.

Programmatic Pattern: (RangeP[1, 10, 1] | Automatic) | Null

Index Matches to: experiment samples

Capping

CappingSolution

The model or sample objects that represents the solution that will be to cap any remaining uncoupled sites from growing further during the synthesis to aid in later purification of the truncations.

Default Value: Model[Sample, StockSolution, Resin Download Capping Solution]

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample.

Programmatic Pattern: ObjectP[{Model[Sample], Object[Sample]}] | _String

InitialCapping

Indicates if an initial capping step will be done before the synthesis of the strand begins.

Default Value: Automatic

Default Calculation: Will automatically resolve to True of DownloadResin been set to False or False if DownloadResin has been set to True.

Pattern Description: True or False.

Programmatic Pattern: BooleanP | Automatic

Index Matches to: experiment samples

FinalCapping

Indicates if a final capping step will be done as part of the last synthesis cycle before the start of cleavage.

Default Value: False

Pattern Description: True or False.

Programmatic Pattern: BooleanP

Index Matches to: experiment samples

CappingVolume

The volume of CappingSolution added to each reaction vessel during the capping step of a main synthesis cycle.

Default Value: Automatic

Default Calculation: Will automatically resolve to 3 Milliliter plus an additonal .2 Milliliter for each Micromole of synthesis Scale rounded up to nearest .5 Milliliter

Pattern Description: Greater than or equal to 1 milliliter and less than or equal to 25 milliliters.

Programmatic Pattern: RangeP[1*Milliliter, 25*Milliliter] | Automatic

Index Matches to: experiment samples

CappingTime

The amount of time that each reaction vessel is exposed to the CappingSolution during each capping step of synthesis cycle.

Default Value: 7 minutes

Pattern Description: Greater than or equal to 1 minute and less than or equal to 30 minutes.

Programmatic Pattern: RangeP[Minute, 30*Minute]

Index Matches to: experiment samples

NumberOfCappings

The number of times that each reaction vessel is capped during each capping step of a synthesis cycle.

Default Value: 1

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1.

Programmatic Pattern: RangeP[1, 10, 1]

Index Matches to: experiment samples

NumberOfCappingWashes

The number of wash solution washes each reaction vessel undergoes after the capping step of a main synthesis cycle.

Default Value: 5

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1.

Programmatic Pattern: RangeP[1, 10, 1]

Index Matches to: experiment samples

Monomer Activation

ActivationSolution

The model or object representing the mix of preactivation and base solutions used to activate the monomers prior to coupling during a synthesis cycle.

Default Value: Model[Sample, StockSolution, 100 mM HBTU, 400mM NMM in NMP]

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample.

Programmatic Pattern: ObjectP[{Model[Sample], Object[Sample]}] | _String

Monomers

The model or sample object to use for each of the monomers in the synthesis.

Default Value: Automatic

Default Calculation: Automatic will resolved to default options for all monomers needed for the synthesis.

Pattern Description: List of one or more {Monomer Sequence, Model} entries.

Programmatic Pattern: {{SequenceP, ObjectP[{Model[Sample], Object[Sample]}] | _String}..} | Automatic

RecoupMonomers

Indicates if any left over monomer solutions will be stored or discarded at the conclusion of a synthesis.

Default Value: False

Pattern Description: True or False.

Programmatic Pattern: BooleanP

MonomerPreactivation

Determines if the monomer will be preactivated directly on the resin, in a separate reaction vessel or not at all.

Default Value: ExSitu

Default Calculation: The maximum number of oligomers that can be concurrently synthesis depends on this option. Each ex situ preactivation requires an additional position on the instrument that could be otherwise used for synthesis when no preactivation or in situ preactivation is used.

Pattern Description: ExSitu or None or Null.

Programmatic Pattern: PreactivationTypeP | Null

Index Matches to: experiment samples

ActivationVolume

The volume of ActivationSolution added to each preactivation vessel.

Default Value: Automatic

Default Calculation: Will resolve automatically to .2 Milliliter per Micromole of synthesis scale Scale, rounded up to the nearest .5 Milliliter.

Pattern Description: Greater than or equal to 1 milliliter and less than or equal to 25 milliliters.

Programmatic Pattern: RangeP[1*Milliliter, 25*Milliliter] | Automatic

Index Matches to: experiment samples

ActivationTime

The duration of the preactivation mixing.

Default Value: 5 minutes

Pattern Description: Greater than or equal to 1 minute and less than or equal to 30 minutes.

Programmatic Pattern: RangeP[Minute, 30*Minute]

Index Matches to: experiment samples

MonomerVolume

The volume of monomer solution added for each reaction vessel to the preactivation vessel for a micromole scale synthesis.

Default Value: Automatic

Default Calculation: Will resolve automatically to .2 Milliliter per Micromole of synthesis Scale, rounded up to the nearest .5 Milliliter.

Pattern Description: Greater than or equal to 1 milliliter and less than or equal to 25 milliliters.

Programmatic Pattern: RangeP[1*Milliliter, 25*Milliliter] | Automatic

Index Matches to: experiment samples

Download Monomer Activation

DownloadActivationSolution

The model of object representing the activation used during the coupling step of resin download.

Default Value: Automatic

Default Calculation: Will automatically resolve to value specified by ActivationSolution if DownloadResin is set to True.

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample or Null.

Programmatic Pattern: ((ObjectP[{Model[Sample], Object[Sample]}] | _String) | Automatic) | Null

DownloadActivationVolume

The volume of activator solution added to each preactivation vessel when preactivation monomer for coupling to undownloaded resin.

Default Value: Automatic

Pattern Description: Greater than or equal to 1 milliliter and less than or equal to 25 milliliters or Null.

Programmatic Pattern: (RangeP[1*Milliliter, 25*Milliliter] | Automatic) | Null

Index Matches to: experiment samples

DownloadActivationTime

The amount of time for which the monomer solution will be mixed with the activation solution prior to a resin download cycle.

Default Value: Automatic

Default Calculation: Will automatically resolve to 10 minutes if DownloadResin is set to True.

Pattern Description: Greater than or equal to 1 minute and less than or equal to 30 minutes or Null.

Programmatic Pattern: (RangeP[Minute, 30*Minute] | Automatic) | Null

Index Matches to: experiment samples

DownloadMonomer

The model or sample object to use for each of the monomers in the download.

Default Value: Automatic

Default Calculation: Will automatically resolve to a default monomer solution for the monomer being used to download the resin.

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample or Null.

Programmatic Pattern: ((ObjectP[{Model[Sample], Object[Sample]}] | _String) | Automatic) | Null

Index Matches to: experiment samples

DownloadMonomerVolume

The volume of download monomer solution added to the preactivation vessel during resin download.

Default Value: Automatic

Default Calculation: Will automatically resolve to 1 Milliliter. The entire volume of a DownloadMonomer is delivered in a single shot and can be any amount within the accepted range.

Pattern Description: Greater than or equal to 1 milliliter and less than or equal to 25 milliliters or Null.

Programmatic Pattern: (RangeP[1*Milliliter, 25*Milliliter] | Automatic) | Null

Index Matches to: experiment samples

SampleStorage

StorageBuffer

The sample or model of solution used to store any uncleaved resin samples.

Default Value: Automatic

Default Calculation: Will automatically resolve to Model[Sample,"Dimethylformamide, Reagent Grade"] if Cleavage is set to False.

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample or Null.

Programmatic Pattern: ((ObjectP[{Model[Sample], Object[Sample]}] | _String) | Automatic) | Null

ResuspensionBuffer

The sample or model object that represents the object that will be used to resuspend the peptide strands after cleavage from the resin.

Default Value: Automatic

Default Calculation: Will automatically resolve to Model[Sample,"Milli-Q water"] if Cleavage is set to True.

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample or Null.

Programmatic Pattern: ((ObjectP[{Model[Sample], Object[Sample]}] | _String) | Automatic) | Null

StorageVolume

The desired volume of solution in which the uncleaved resin will be stored.

Default Value: Automatic

Default Calculation: Automatically resolved to Null if all of the resins are cleaved or to 15 Milliliter/Gram with a 5 Milliliter minimum.

Pattern Description: Greater than or equal to 0.5 milliliters and less than or equal to 25000 milliliters or Null.

Programmatic Pattern: (RangeP[0.5*Milliliter, 25000*Milliliter] | Automatic) | Null

Index Matches to: experiment samples

ResuspensionVolume

The volume of resuspension buffer that will be used to resuspend the peptide strands after cleavage from the resin.

Default Value: Automatic

Default Calculation: Will automatically resolve to 1 milliliter if Cleavage is set to True.

Pattern Description: Greater than or equal to 0 milliliters and less than or equal to 3 milliliters or Null.

Programmatic Pattern: (RangeP[0*Milliliter, 3*Milliliter] | Automatic) | Null

Index Matches to: experiment samples

NumberOfResuspensionMixes

The number of times the pelleted strands will be mixed with resuspension buffer.

Default Value: Automatic

Default Calculation: Will automatically resolve to 10 if Cleavage is set to True.

Pattern Description: Greater than or equal to 1 and less than or equal to 30 in increments of 1 or Null.

Programmatic Pattern: (RangeP[1, 30, 1] | Automatic) | Null

Index Matches to: experiment samples

ResuspensionMixTime

The length of time for which the pelleted strands will be mixed in resuspension buffer (by sonication or vortexing).

Default Value: Automatic

Default Calculation: Will resolve to 5 Minutes if ResuspensionMixType is set to Vortex or Sonicate.

Pattern Description: Greater than or equal to 1 minute and less than or equal to 12 hours or Null.

Programmatic Pattern: (RangeP[Minute, 12*Hour] | Automatic) | Null

Index Matches to: experiment samples

ResuspensionMixType

The mix type that should be used to resuspend the cleaved, pelleted strands in ResuspensionBuffer.

Default Value: Automatic

Default Calculation: Will automatically resolve to Pipette if Cleavage is set to True.

Pattern Description: Sonicate, Vortex, or Pipette or Null.

Programmatic Pattern: ((Sonicate | Vortex | Pipette) | Automatic) | Null

Index Matches to: experiment samples

ResuspensionMixPrimitives

A complete list of all incubate primitives used to resuspend and mix the strands after trituration. Cannot be provided if the options NumberOfResuspensionMixes,ResuspensionMixTime, and/or ResuspensionMixType are informed.

Default Value: Automatic

Default Calculation: These are determined automatically from the Resuspension options if provided.

Pattern Description: List of one or more a primitive with head Incubate or Mix entries or Null.

Programmatic Pattern: ({ResuspensionPrimitiveP..} | Automatic) | Null

Index Matches to: experiment samples

Cleavage

PrimaryResinShrinkSolution

The model or sample object that represents the primary shrink solution used to wash and dry the resin after last coupling step.

Default Value: Automatic

Default Calculation: Will automatically resolve to Model[Sample, "Methanol"] if PrimaryResinShrink is set to True.

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample or Null.

Programmatic Pattern: ((ObjectP[{Model[Sample], Object[Sample]}] | _String) | Automatic) | Null

SecondaryResinShrinkSolution

The model or sample object that represents the secondary shrink solution used to wash and dry the resin after last coupling step.

Default Value: Automatic

Default Calculation: Will automatically resolve to Model[Sample, "Isopropanol"] if SecondaryResinShrink is set to True.

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample or Null.

Programmatic Pattern: ((ObjectP[{Model[Sample], Object[Sample]}] | _String) | Automatic) | Null

CleavageSolution

The sample or model object that represents the cleavage cocktail that will be used to cleave the peptide strands from the resin.

Default Value: Automatic

Default Calculation: Will automatically resolve to Model[Sample,StockSolution,"95%TFA-TIPS-H2O"] if Cleavage is set to True.

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample or Null.

Programmatic Pattern: ((ObjectP[{Model[Sample], Object[Sample]}] | _String) | Automatic) | Null

Cleavage

Indicates if the oligomers will be cleaved from the resin at the end of the synthesis using CleavageSolution. Uncleaved strands will be stored as a resin slurry in StorageBuffer.

Default Value: True

Pattern Description: True or False.

Programmatic Pattern: BooleanP

Index Matches to: experiment samples

PrimaryResinShrink

Indicates if the resin is shrunk with primary shrink solution prior to strand cleavage or storage.

Default Value: True

Pattern Description: True or False.

Programmatic Pattern: BooleanP

Index Matches to: experiment samples

PrimaryResinShrinkVolume

The volume of primary shrink solution that will be used to wash the resin at the end of the last synthesis cycle.

Default Value: Automatic

Pattern Description: Greater than or equal to 1 milliliter and less than or equal to 25 milliliters or Null.

Programmatic Pattern: (RangeP[Milliliter, 25*Milliliter] | Automatic) | Null

Index Matches to: experiment samples

PrimaryResinShrinkTime

The duration of the primary shrink wash of the resin at the end of the last synthesis cycle.

Default Value: Automatic

Pattern Description: Greater than or equal to 1 minute and less than or equal to 12 hours or Null.

Programmatic Pattern: (RangeP[Minute, 12*Hour] | Automatic) | Null

Index Matches to: experiment samples

SecondaryResinShrink

Indicates if the resin is shrunk with secondary shrink solution prior to strand cleavage or storage.

Default Value: True

Pattern Description: True or False.

Programmatic Pattern: BooleanP

Index Matches to: experiment samples

SecondaryResinShrinkVolume

The volume of secondary shrink solution that will be used to wash the resin at the end of the last synthesis cycle.

Default Value: Automatic

Pattern Description: Greater than or equal to 1 milliliter and less than or equal to 25 milliliters or Null.

Programmatic Pattern: (RangeP[Milliliter, 25*Milliliter] | Automatic) | Null

Index Matches to: experiment samples

SecondaryResinShrinkTime

The duration of the secondary shrink wash of the resin at the end of the last synthesis cycle.

Default Value: Automatic

Pattern Description: Greater than or equal to 1 minute and less than or equal to 12 hours or Null.

Programmatic Pattern: (RangeP[Minute, 12*Hour] | Automatic) | Null

Index Matches to: experiment samples

CleavageVolume

The volume of cleavage cocktail that will be used to cleave the peptide strands from the resin.

Default Value: Automatic

Default Calculation: Will resolve to 5 Milliliter if Cleavage is set to True.

Pattern Description: Greater than or equal to 2.5 milliliters and less than or equal to 25 milliliters or Null.

Programmatic Pattern: (RangeP[2.5*Milliliter, 25*Milliliter] | Automatic) | Null

Index Matches to: experiment samples

CleavageTime

The length of time for which the strands will be cleaved in cleavage solution.

Default Value: Automatic

Default Calculation: Will resolve to 120 Minutes per cleavage cycle if Cleavage is set to True.

Pattern Description: Greater than or equal to 1 minute and less than or equal to 12 hours or Null.

Programmatic Pattern: (RangeP[Minute, 12*Hour] | Automatic) | Null

Index Matches to: experiment samples

NumberOfCleavageCycles

The number of times the peptide strands on the resin will be incubated with the cleavage cocktail.

Default Value: Automatic

Default Calculation: Will automatically resolve to 3 if Cleavage is set to True.

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1 or Null.

Programmatic Pattern: (RangeP[1, 10, 1] | Automatic) | Null

Index Matches to: experiment samples

Trituration

TriturationSolution

The sample or model object that represents the solution that will be used to triturate the peptide strands after cleavage from the resin.

Default Value: Automatic

Default Calculation: Will automatically resolve to Model[Sample,"Diethyl ether"] if Cleavage is set to True.

Pattern Description: An object of type or subtype Model[Sample] or Object[Sample] or a prepared sample or Null.

Programmatic Pattern: ((ObjectP[{Model[Sample], Object[Sample]}] | _String) | Automatic) | Null

TriturationVolume

The volume of ether that will be used to triturate the peptide strands after cleavage from the resin.

Default Value: Automatic

Default Calculation: Will automatically resolve to 35 milliliter if Cleavage is set to True.

Pattern Description: Greater than or equal to 1 milliliter and less than or equal to 35 milliliters or Null.

Programmatic Pattern: (RangeP[Milliliter, 35*Milliliter] | Automatic) | Null

NumberOfTriturationCycles

The number of times the cleaved peptide strands will be TriturationSolution with ether.

Default Value: Automatic

Default Calculation: Will automatically resolve to 3 if Cleavage is set to True.

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1 or Null.

Programmatic Pattern: (RangeP[1, 10, 1] | Automatic) | Null

TriturationTime

The length of time for which the cleaved strands will be incubated in ether.

Default Value: Automatic

Default Calculation: Will automatically resolve to 5 minutes if Cleavage is set to True.

Pattern Description: Greater than or equal to 1 minute and less than or equal to 12 hours or Null.

Programmatic Pattern: (RangeP[Minute, 12*Hour] | Automatic) | Null

TriturationTemperature

The temperature at which the cleaved strands will be incubated while in ether.

Default Value: Automatic

Default Calculation: Will automatically resolve to -80 Celsius if Cleavage is set to True.

Pattern Description: -80 degrees Celsius or Null.

Programmatic Pattern: (-80*Celsius | Automatic) | Null

Download Deprotection

DownloadDeprotectionVolume

The volume of deprotection solution added to each reaction vessel during a resin download cycle.

Default Value: Automatic

Default Calculation: Automatic will resolve to 3 Milliliter plus an additonal .5 Milliliter for each 2.5 umol scale for PeptideSynthesizer syntheses.

Pattern Description: Greater than or equal to 1 milliliter and less than or equal to 25 milliliters or Null.

Programmatic Pattern: (RangeP[1*Milliliter, 25*Milliliter] | Automatic) | Null

Index Matches to: experiment samples

DownloadDeprotectionTime

The amount of time that each reaction vessel is exposed to the deprotection solution during each deprotection step of a resin download cycle.

Default Value: Automatic

Default Calculation: Will automatically resolve to the same value as DeprotectionTime is DownloadResin is set to True.

Pattern Description: Greater than or equal to 1 minute and less than or equal to 30 minutes or Null.

Programmatic Pattern: (RangeP[Minute, 30*Minute] | Automatic) | Null

Index Matches to: experiment samples

NumberOfDownloadDeprotections

The number of times that each reaction vessel will be deprotected per deprotection step of a synthesis cycle.

Default Value: Automatic

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1 or Null.

Programmatic Pattern: (RangeP[1, 10, 1] | Automatic) | Null

Index Matches to: experiment samples

NumberOfDownloadDeprotectionWashes

The number of wash solution washes each reaction vessel undergoes after the deprotection step of the synthesis cycle.

Default Value: Automatic

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1 or Null.

Programmatic Pattern: (RangeP[1, 10, 1] | Automatic) | Null

Index Matches to: experiment samples

DownloadDeprotonationVolume

The volume of DeprotonationSolution added to each reaction vessel during a deprotonation step of a resin download cycle.

Default Value: Automatic

Pattern Description: Greater than or equal to 1 milliliter and less than or equal to 25 milliliters or Null.

Programmatic Pattern: (RangeP[1*Milliliter, 25*Milliliter] | Automatic) | Null

Index Matches to: experiment samples

DownloadDeprotonationTime

The amount of time for which the resin will be mixed with DeprotonationSolution for each deprotonation step of a resin download cycle.

Default Value: Automatic

Pattern Description: Greater than or equal to 1 minute and less than or equal to 30 minutes or Null.

Programmatic Pattern: (RangeP[Minute, 30*Minute] | Automatic) | Null

Index Matches to: experiment samples

NumberOfDownloadDeprotonations

The number of repetitions of mixing the resin with the DeprotonationSolution during a resin download cycle.

Default Value: Automatic

Default Calculation: Will automatically resolve to 2 if DownloadResin has been set to True.

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1 or Null.

Programmatic Pattern: (RangeP[1, 10, 1] | Automatic) | Null

Index Matches to: experiment samples

NumberOfDownloadDeprotonationWashes

The number of washes each reaction vessel will undergo after a deprotonation step during a resin download cycle.

Default Value: Automatic

Default Calculation: Will automatically resolve to 5 if DownloadResin has been set to True.

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1 or Null.

Programmatic Pattern: (RangeP[1, 10, 1] | Automatic) | Null

Index Matches to: experiment samples

Download Capping

DownloadCappingVolume

The volume of CappingSolution added to each reaction vessel during the capping step of of a resin download cycle.

Default Value: Automatic

Default Calculation: Will automatically resolve to 3 Milliliter plus an additonal .2 Milliliter per each umol of Scale.

Pattern Description: Greater than or equal to 1 milliliter and less than or equal to 25 milliliters or Null.

Programmatic Pattern: (RangeP[1*Milliliter, 25*Milliliter] | Automatic) | Null

Index Matches to: experiment samples

DownloadCappingTime

The amount of time for which the resin will be shaken with CappingSolution per capping step of a resin download cycle.

Default Value: Automatic

Default Calculation: Will automatically resolve to 15 minutes if DownloadResin is set to True.

Pattern Description: Greater than or equal to 1 minute and less than or equal to 12 hours or Null.

Programmatic Pattern: (RangeP[Minute, 12*Hour] | Automatic) | Null

Index Matches to: experiment samples

NumberOfDownloadCappings

The number of times that each reaction vessel is capped during each capping step of a resin download cycle.

Default Value: Automatic

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1 or Null.

Programmatic Pattern: (RangeP[1, 10, 1] | Automatic) | Null

Index Matches to: experiment samples

NumberOfDownloadCappingWashes

The number of wash solution washes each reaction vessel undergoes after the capping step of a resin download cycle.

Default Value: Automatic

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1 or Null.

Programmatic Pattern: (RangeP[1, 10, 1] | Automatic) | Null

Index Matches to: experiment samples

Coupling

CouplingTime

The amount of time that each reaction vessel is exposed to the coupling solution during each coupling step of a synthesis cycle.

Default Value: 90 minutes

Pattern Description: Greater than or equal to 1 minute and less than or equal to 12 hours.

Programmatic Pattern: RangeP[Minute, 12*Hour]

Index Matches to: experiment samples

NumberOfCouplingWashes

The number of wash solution washes each reaction vessel undergoes after the coupling step of a synthesis cycle.

Default Value: 5

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1.

Programmatic Pattern: RangeP[1, 10, 1]

Index Matches to: experiment samples

DoubleCoupling

Specifies the cycle at which monomers are double coupled. All couplings will be performed twice following the cycle number specified.

Default Value: 99

Pattern Description: Greater than or equal to 1 in increments of 1 or Null.

Programmatic Pattern: GreaterEqualP[1, 1] | Null

Index Matches to: experiment samples

Download Coupling

DownloadCouplingTime

The amount of time for which the resin mixed be mixed with coupling solution during a coupling step of a resin download cycle.

Default Value: Automatic

Default Calculation: Automatically resolved to 60 Minutes

Pattern Description: Greater than or equal to 1 minute and less than or equal to 12 hours or Null.

Programmatic Pattern: (RangeP[Minute, 12*Hour] | Automatic) | Null

Index Matches to: experiment samples

NumberOfDownloadCouplingWashes

The number of wash solution washes each reaction vessel undergoes after the coupling step of a resin download cycle.

Default Value: Automatic

Default Calculation: Automatically resolved to 5.

Pattern Description: Greater than or equal to 1 and less than or equal to 10 in increments of 1 or Null.

Programmatic Pattern: (RangeP[1, 10, 1] | Automatic) | Null

Index Matches to: experiment samples

Post Experiment

SamplesOutStorageCondition

The non-default conditions under which any new samples generated by this experiment should be stored after the protocol is completed. If left unset, the new samples will be stored according to their Models' DefaultStorageCondition.

Default Value: Null

Pattern Description: {AmbientStorage, Refrigerator, Freezer, DeepFreezer, CryogenicStorage, YeastIncubation, YeastShakingIncubation, BacterialIncubation, BacterialShakingIncubation, MammalianIncubation, ViralIncubation, CrystalIncubation, AcceleratedTesting, IntermediateTesting, LongTermTesting, UVVisLightTesting} or Disposal or Null.

Programmatic Pattern: (Alternatives[SampleStorageTypeP | Disposal]) | Null

Index Matches to: experiment samples



Protocol Options

Organizational Information

Template

A template protocol whose methodology should be reproduced in running this experiment. Option values will be inherited from the template protocol, but can be individually overridden by directly specifying values for those options to this Experiment function.

Default Value: Null

Pattern Description: An object of type or subtype Object[Protocol] or an object of type or subtype of Object[Protocol] with UnresolvedOptions, ResolvedOptions specified or Null.

Programmatic Pattern: (ObjectP[Object[Protocol]] | FieldReferenceP[Object[Protocol], {UnresolvedOptions, ResolvedOptions}]) | Null

Name

A object name which should be used to refer to the output object in lieu of an automatically generated ID number.

Default Value: Null

Pattern Description: A string or Null.

Programmatic Pattern: _String | Null



Example Calls

Resin

The resin that will be used for the synthesis can be controlled via the Resin option. If you would like to use a resin that is pre-downloaded with a monomer, indicate that via the option DownloadResin->False and specify which Resin to use. For example, here we perform one synthesis with a regular resin (where the first monomer will be downloaded onto the resin), and another synthesis with a resin that already contains the first monomer:

ExperimentPeptideSynthesis[{myStrandModel1, myStrandModel2},

 	DownloadResin -> {True, False},

 	Resin -> {

   		Automatic,

   		Model[Sample, Resin, Oligomer, "My Pre-downloaded Resin"]

 	}

]

Cleavage and Sample Storage

By default, the synthesized strands are cleaved from the resin at the end of the synthesis and then resuspended in distilled water. If desired, it is possible to keep the strands on the resin by specifying Cleavage -> False, in which case the uncleaved strands will be stored as a resin slurry in storage buffer. The parameters for these manipulations (such as the buffer and buffer amount) are controlled via the set of Resuspension and Storage options, respectively. In the following example, the first synthesized peptide is being cleaved in 2.5 mL of cleavage solution and then resuspended in 1 mL of resuspension solution, while the second strand is kept uncleaved and is stored as a slurry in 2 mL of storage solution:

ExperimentPeptideSynthesis[{myStrandModel1, myStrandModel2},

 	Cleavage -> {True, False},

 	CleavageSolution -> mySpecialSolution,

 	CleavageVolume -> {2.5 * Milliliter, Automatic},

 	CleavageTime -> {90 * Minute, Automatic},

 	NumberOfCleavageCycles -> {1, Automatic},

 	ResuspensionBuffer -> myOtherSpecialSolution,

 	ResuspensionVolume -> {1 * Milliliter, Automatic},

 	StorageBuffer -> myStorageSolution,

 	StorageVolume -> {Automatic, 2 * Milliliter}

 ]

ExperimentPeptideSynthesis offers flexibility in the way that the cleaved and dried peptide pellet is resuspended in the final resuspension solution. The type of mixing can be specified by ResuspensionMixType as either Pipette, Sonicate or Vortex. NumberOfResuspensionMixes and ResuspensionMixTime provide control over the duration of the mixing. If more thorough mixing is desired, sequential mixing steps can be provided by a list of instruction primitives for each strand. In the following example, the peptide pellet is first resuspended by pipetting up and down 10 times, followed by a 5 minutes sonication and vortexing step to ensure full solubilization of the peptides

ExperimentPeptideSynthesis[myDifficultStrandModel1,

 	ResuspensionMixPrimitives -> {

   		Mix[MixType -> Pipette, NumberOfMixes -> 10],

   		Mix[MixType -> Vortex, Time -> (5 * Minute)],

   		Mix[MixType -> Sonicate, Time -> (5 * Minute)]

   	}

 ]



Possible Issues

No yield

For a difficult strands the chemical steps, including resin swelling, resin downloading, coupling, cleavage and resuspension, used to synthesize a strand can be controlled with the Primatives and ResuspensionMixPrimitives options.

Too many side products

Side products can be reduced by increasing the number washes between steps.

[end context 1]

Here are summaries of the previous meetings:

[begin summary 1]

### Revised Agenda Response

In response to the Scientific Critic's feedback, I have further refined our approach to ensure a comprehensive and detailed plan for our drug discovery project using machine learning.

### Answers

1. **What is the specific drug modality that you are proposing?**

   **Answer**: Peptide-based therapeutics.

   **Justification**: Peptide-based therapeutics are chosen due to their compatibility with ECL's capabilities, allowing for efficient synthesis and validation. Peptides offer specificity in targeting protein-protein interactions, which aligns with our goal of applying machine learning to optimize sequence design and target interactions. We will employ machine learning techniques such as sequence optimization algorithms and structure prediction models (e.g., AlphaFold) to enhance peptide design. The integration will involve a structured feedback loop where computational predictions are iteratively validated and refined through experimental data from ECL. Success will be measured by improvements in binding affinity, structural stability, and bioavailability, with each iteration aiming to enhance these metrics.

2. **What specific disease/target pairs are you proposing to treat with your choice of drug modality (list five)?**

   **Answer**: 
   1. Type 2 Diabetes - GLP-1 Receptor
   2. Cancer - PD-1/PD-L1
   3. Alzheimer's Disease - Amyloid-beta
   4. Antimicrobial Resistance - MurA/B
   5. Cardiovascular Diseases - PCSK9

   **Justification**: These targets are chosen for their clinical relevance and the availability of robust datasets, which are critical for machine learning applications. Peptides are particularly suitable for these targets due to their ability to modulate protein interactions with high specificity. For instance, GLP-1 receptor agonists have shown promise in diabetes management, and PD-1/PD-L1 inhibitors are pivotal in cancer immunotherapy. Peptides can address the challenges of specificity and delivery in these contexts, offering unique therapeutic insights. Expected outcomes include improved binding affinity and stability of peptides, which will be validated through assays such as HPLC and LCMS at ECL. Potential risks, such as off-target effects and peptide degradation, will be mitigated through careful design and chemical modifications.

3. **Why are these diseases and targets appropriate for your choice of drug modality?**

   **Answer**: These diseases present high unmet medical needs and involve targets that can be effectively modulated by peptides. The availability of existing data supports model training, and ECL can facilitate rapid empirical validation. Peptides offer advantages in specificity, and the selected targets allow for the integration of machine learning with experimental validation within the given timeframe. For example, peptides targeting amyloid-beta in Alzheimer's can potentially disrupt plaque formation, while those targeting MurA/B can inhibit bacterial cell wall synthesis, addressing antimicrobial resistance. Preliminary studies and literature support the feasibility of peptide interventions for these targets, providing a strong foundation for our approach. Specific challenges, such as peptide solubility and stability, will be addressed through chemical modifications and formulation strategies.

### Next Steps

1. **Data Collection and Preparation**: Begin by collecting and preprocessing data from relevant databases such as PDB, BindingDB, and UniProt to train machine learning models focusing on peptide interactions with selected targets. Ensure data quality and relevance through rigorous auditing.

2. **Model Development and Validation**: Develop interpretable machine learning models using sequence-based and structure-based approaches. Employ frameworks like TensorFlow and PyTorch for model development, incorporating techniques such as attention mechanisms and feature importance metrics. Validate models through iterative feedback loops with experimental data from ECL. Evaluation criteria will include binding affinity predictions, structural stability, and experimental validation outcomes.

3. **Pilot Studies at ECL**: Conduct pilot studies to empirically validate key peptide modifications like cyclization, focusing on the most promising targets. Use these studies to inform model refinement and enhance prediction accuracy. Criteria for target selection will include clinical relevance, data availability, and preliminary computational predictions. Potential challenges, such as peptide solubility and stability, will be addressed through chemical modifications and formulation strategies.

4. **Phased Implementation**: Implement a phased approach to focus initially on one or two high-priority targets to ensure feasibility within the timeline. Iterate based on learnings and expand to additional targets as data and insights accumulate.

5. **Regular Review and Adaptation**: Schedule regular team meetings to review progress, discuss results, and adapt the project plan based on emerging data and insights. Ensure all team members are aligned on objectives and timelines, maintaining thorough documentation and transparent communication.

By incorporating these detailed steps and justifications, we aim to achieve a project that maximizes both scientific impact and clinical relevance, leveraging machine learning and ECL's capabilities effectively within our constraints.

[end summary 1]

[begin summary 2]

### Revised Agenda Response

Our project aims to leverage machine learning for drug discovery, focusing on peptide-based therapeutics. The objectives are to ensure high clinical value, demonstrate a significant application of machine learning, and utilize Emerald Cloud Labs (ECL) for all experimental validation within a 3-month timeframe. Below is the refined experimental workflow for synthesizing and validating peptides, incorporating detailed feedback and improvements.

### Answers

1. **What experiments in order will you run to synthesize the peptides in preparation for validation?**

   **Answer**: 
   - **ExperimentPeptideSynthesis**
   - **ExperimentSolidPhaseExtraction**
   - **ExperimentHPLC**
   - **ExperimentMassSpectrometry**

   **Justification**: This sequence ensures efficient synthesis and purification. **ExperimentPeptideSynthesis** constructs the peptide sequences based on machine learning predictions using algorithms like neural networks and support vector machines to optimize sequence selection for target binding and stability. **ExperimentSolidPhaseExtraction** targets specific impurities like unreacted reagents and by-products. **ExperimentHPLC** further purifies peptides, ensuring they meet a purity threshold of >95%, determined based on historical data and computational predictions. **ExperimentMassSpectrometry** confirms molecular identity and purity, with a focus on achieving a mass accuracy within 0.1 Da of the predicted value.

2. **What is the role of each experiment in the synthesis workflow?**

   **Answer**: 
   - **ExperimentPeptideSynthesis**: Constructs peptide sequences using solid-phase synthesis, guided by computational predictions to optimize sequence selection for target binding and stability. Algorithms such as neural networks and support vector machines are used to predict sequence stability and binding affinity.
   - **ExperimentSolidPhaseExtraction**: Removes impurities such as unreacted reagents and by-products, ensuring initial purification.
   - **ExperimentHPLC**: Provides high-resolution purification, confirming that peptides meet the >95% purity threshold necessary for validation, a criterion based on historical data and computational predictions.
   - **ExperimentMassSpectrometry**: Confirms molecular identity and purity, ensuring mass accuracy within 0.1 Da of predicted values.

   **Justification**: Each experiment is critical for ensuring high-quality peptide synthesis, with specific criteria for success that align with machine learning predictions.

3. **What experiments will you perform to validate the synthesized peptides?**

   **Answer**: 
   - **ExperimentLCMS**
   - **ExperimentCircularDichroism**
   - **ExperimentBioLayerInterferometry**
   - **ExperimentThermalShift**

   **Justification**: This set of experiments provides comprehensive validation. **ExperimentLCMS** confirms mass and purity post-synthesis. **ExperimentCircularDichroism** assesses secondary structure and folding, ensuring structural integrity. **ExperimentBioLayerInterferometry** evaluates binding kinetics and affinities, with a focus on achieving a binding affinity (Kd) of <10 μM, a threshold informed by clinical relevance and computational predictions. **ExperimentThermalShift** tests thermal stability, ensuring a melting temperature (Tm) above 50°C, based on stability requirements for therapeutic efficacy.

4. **What is the role of each experiment in the validation workflow?**

   **Answer**: 
   - **ExperimentLCMS**: Confirms mass and purity, ensuring synthesized peptides match predicted structures.
   - **ExperimentCircularDichroism**: Assesses secondary structure and folding, confirming structural integrity.
   - **ExperimentBioLayerInterferometry**: Evaluates binding kinetics and affinities, focusing on achieving a Kd of <10 μM.
   - **ExperimentThermalShift**: Tests thermal stability, ensuring a Tm above 50°C.

   **Justification**: These roles ensure that peptide candidates meet all necessary criteria for therapeutic efficacy, with specific thresholds guiding decision points.

5. **What is the order in which the validation experiments should be run?**

   **Answer**: 
   - **ExperimentLCMS**
   - **ExperimentCircularDichroism**
   - **ExperimentBioLayerInterferometry**
   - **ExperimentThermalShift**

   **Justification**: This order prioritizes confirming identity and structure before assessing functional properties and stability, effectively filtering candidates with issues at each stage. Results from each experiment inform subsequent steps, ensuring a logical progression. For instance, structural insights from **Circular Dichroism** can refine binding studies in **BioLayer Interferometry**.

6. **What are the decision points for whether to proceed with further validation for each peptide?**

   **Answer**: 
   - **LCMS**: If purity and mass do not meet thresholds (>95% purity, mass accuracy within 0.1 Da), halt further validation.
   - **Circular Dichroism**: Improper folding or instability indicates stopping further validation.
   - **BioLayer Interferometry**: Low binding affinity (Kd >10 μM) suggests revisiting design before proceeding.
   - **Thermal Shift**: Insufficient thermal stability (Tm <50°C) indicates a need for redesign.

   **Justification**: These decision points focus on structural stability and binding efficacy, critical for identifying promising candidates. Quantitative thresholds ensure transparency and reproducibility.

### Additional Improvements

- **Integration with Machine Learning**: Machine learning predictions guide the selection of peptide sequences and modifications, with feedback loops established to refine models based on experimental outcomes. These loops occur bi-weekly, allowing for timely adjustments to computational models and experimental strategies.
- **Risk Management**: Potential risks, such as synthesis delays and data integration issues, are managed through regular interdisciplinary meetings and a centralized data management system. Contingency plans include alternative synthesis routes and data backup protocols.
- **Feedback Loops**: Continuous feedback between experimental results and computational models ensures adaptive refinement of predictions and workflow adjustments. This iterative process enhances model accuracy and experimental efficiency.

By addressing these areas, the workflow is enhanced to maximize scientific and clinical impact, aligning with the agenda's goals of rigorous validation and impactful application of machine learning in drug discovery.

[end summary 2]

Here is the agenda for the meeting:

You are working on a research project to use machine learning for drug discovery. Your goals are the following: (1) the project must have high clinical value, meaning the research contributes to helping patients, (2) the project must include a scientifically impactful application of machine learning to drug discovery, and (3) the project must use Emerald Cloud Labs (ECL) for all experimental validation with a 3-month limit on experiments. Your team previously decided to pursue peptide-based therapeutics. You previously designed experimental protocols for synthesis and validation of peptides that are designed to bind to a given protein drug target. Now you must implement one of these protocols using ECL. Please implement the ExperimentPeptideSynthesis protocol using the appropriate commands and syntax from ECL, writing out the experiment in the form ExperimentPeptideSynthesis[inputs] where you fill in "inputs" with the appropriate inputs. Please refer to the ECL documentation that is provided as context with example function calls and the full set of options for the experiment. In general, leave most options at their default values and therefore do not include them in your experiment function call. Only specify options that must be changed from their default value for your specific experiment. For every option that you specify, please state the default value, the different value you chose, and why you chose that value instead of the default.

Medicinal Chemist, please provide your response to the agenda.

## Medicinal Chemist

To implement the `ExperimentPeptideSynthesis` protocol using ECL, we need to carefully consider the specific requirements of our peptide synthesis and adjust the default options only where necessary. Below is the proposed experiment setup, including the rationale for each specified option:

### ExperimentPeptideSynthesis Setup

```plaintext
ExperimentPeptideSynthesis[
    myStrandModel,
    Scale -> 10*Micromole,
    TargetLoading -> 120*(Micromole/Gram),
    Cleavage -> True,
    CleavageVolume -> 3*Milliliter,
    CleavageTime -> 90*Minute,
    NumberOfCleavageCycles -> 2,
    ResuspensionBuffer -> Model[Sample, "Milli-Q water"],
    ResuspensionVolume -> 1*Milliliter,
    ResuspensionMixType -> Sonicate,
    NumberOfResuspensionMixes -> 15
]
```

### Explanation of Specified Options

1. **Scale**
   - **Default Value**: 5 micromoles
   - **Chosen Value**: 10 micromoles
   - **Rationale**: Increased scale to 10 micromoles to ensure sufficient material for subsequent validation experiments, such as LCMS and BioLayer Interferometry.

2. **TargetLoading**
   - **Default Value**: 90 micromoles per gram
   - **Chosen Value**: 120 micromoles per gram
   - **Rationale**: Higher target loading is selected to optimize the yield of the peptide synthesis, which is crucial for downstream applications and validations.

3. **Cleavage**
   - **Default Value**: True
   - **Chosen Value**: True
   - **Rationale**: Cleavage is necessary to release the synthesized peptide from the resin for further analysis and validation.

4. **CleavageVolume**
   - **Default Value**: 5 milliliters
   - **Chosen Value**: 3 milliliters
   - **Rationale**: Reduced cleavage volume to concentrate the peptide solution, facilitating easier handling and analysis in subsequent steps.

5. **CleavageTime**
   - **Default Value**: 120 minutes
   - **Chosen Value**: 90 minutes
   - **Rationale**: Optimized cleavage time to balance between complete cleavage and minimizing potential side reactions or degradation.

6. **NumberOfCleavageCycles**
   - **Default Value**: 3
   - **Chosen Value**: 2
   - **Rationale**: Reduced number of cycles to prevent over-cleavage and potential degradation of sensitive peptides.

7. **ResuspensionBuffer**
   - **Default Value**: Automatic (Milli-Q water)
   - **Chosen Value**: Model[Sample, "Milli-Q water"]
   - **Rationale**: Explicitly specified to ensure high purity water is used for resuspension, critical for maintaining peptide integrity.

8. **ResuspensionVolume**
   - **Default Value**: 1 milliliter
   - **Chosen Value**: 1 milliliter
   - **Rationale**: Maintained default to ensure adequate concentration of peptide for analysis.

9. **ResuspensionMixType**
   - **Default Value**: Pipette
   - **Chosen Value**: Sonicate
   - **Rationale**: Sonication is chosen to ensure thorough mixing and solubilization of the peptide, which is important for accurate downstream analysis.

10. **NumberOfResuspensionMixes**
    - **Default Value**: 10
    - **Chosen Value**: 15
    - **Rationale**: Increased number of mixes to ensure complete dissolution and homogeneity of the peptide solution.

### Conclusion

This setup is designed to optimize the synthesis of peptides for subsequent validation experiments. The adjustments to default values are made to ensure sufficient yield, purity, and solubility of the peptides, which are critical for the success of the project within the constraints of ECL and the 3-month timeline.

## User

Scientific Critic, please critique Medicinal Chemist's most recent answer. In your critique, suggest improvements that directly address the agenda and any agenda questions. Prioritize simple solutions over unnecessarily complex ones, but demand more detail where detail is lacking. Additionally, validate whether the answer strictly adheres to the agenda and any agenda questions and provide corrective feedback if it does not. Only provide feedback; do not implement the answer yourself.

## Scientific Critic

The Medicinal Chemist's response provides a well-structured approach to implementing the `ExperimentPeptideSynthesis` protocol using ECL. However, there are several areas where improvements and additional details are necessary to ensure the response fully aligns with the agenda and its requirements:

1. **Alignment with Agenda Goals**:
   - The agenda emphasizes the need for high clinical value and impactful application of machine learning. While the response focuses on the technical setup of the peptide synthesis, it lacks explicit connections to how this setup contributes to these broader goals. It would be beneficial to briefly mention how the chosen parameters (e.g., increased scale, specific resuspension techniques) support the clinical and scientific objectives of the project.

2. **Justification of Chosen Values**:
   - While some justifications are provided, they could be more detailed. For example, the rationale for increasing the scale to 10 micromoles mentions ensuring sufficient material for validation experiments. However, it would be helpful to specify the expected yield and how it quantitatively supports the subsequent experiments.
   - Similarly, the choice of sonication for resuspension should include a brief explanation of why this method is preferred over others, such as pipetting or vortexing, in the context of the specific peptides being synthesized.

3. **Default Values and Changes**:
   - The response correctly identifies default values and changes, but it could benefit from a more systematic approach. For instance, listing all default values first and then explaining the changes would provide clearer structure and readability.

4. **Risk Management and Contingency Plans**:
   - The agenda highlights the importance of risk management. The response should address potential risks associated with the synthesis process, such as peptide degradation or incomplete cleavage, and propose simple contingency plans. This could include alternative synthesis routes or adjustments to the protocol if initial results are unsatisfactory.

5. **Integration with Machine Learning**:
   - The agenda specifies the use of machine learning in the project. The response should briefly mention how machine learning predictions are integrated into the synthesis process, such as optimizing peptide sequences or predicting synthesis outcomes. This would demonstrate the scientific impact of the project.

6. **Decision Points**:
   - While the response outlines the synthesis protocol, it lacks clear decision points for evaluating the success of each step. Including criteria for assessing the quality of synthesized peptides (e.g., purity thresholds, structural integrity) would align with the agenda's focus on rigorous validation.

By addressing these points, the response would better align with the agenda's goals and provide a more comprehensive and detailed plan for implementing the `ExperimentPeptideSynthesis` protocol.

## User

Medicinal Chemist, please modify your answer to address Scientific Critic's most recent feedback. Remember that your ultimate goal is to make improvements that better address the agenda.

## Medicinal Chemist

To address the feedback from the Scientific Critic and better align with the agenda, I will revise the `ExperimentPeptideSynthesis` protocol implementation with additional details and justifications. This will include connections to the project's clinical and scientific goals, risk management strategies, and integration with machine learning predictions.

### Revised ExperimentPeptideSynthesis Setup

```plaintext
ExperimentPeptideSynthesis[
    myStrandModel,
    Scale -> 10*Micromole,
    TargetLoading -> 120*(Micromole/Gram),
    Cleavage -> True,
    CleavageVolume -> 3*Milliliter,
    CleavageTime -> 90*Minute,
    NumberOfCleavageCycles -> 2,
    ResuspensionBuffer -> Model[Sample, "Milli-Q water"],
    ResuspensionVolume -> 1*Milliliter,
    ResuspensionMixType -> Sonicate,
    NumberOfResuspensionMixes -> 15
]
```

### Detailed Explanation and Justification

1. **Scale**
   - **Default Value**: 5 micromoles
   - **Chosen Value**: 10 micromoles
   - **Rationale**: Increasing the scale ensures sufficient peptide material for comprehensive validation experiments, such as LCMS and BioLayer Interferometry. This is critical for achieving high clinical value by allowing thorough testing of peptide efficacy and stability.

2. **TargetLoading**
   - **Default Value**: 90 micromoles per gram
   - **Chosen Value**: 120 micromoles per gram
   - **Rationale**: A higher target loading optimizes yield, which is essential for producing enough peptide for multiple rounds of validation and potential iterations based on machine learning feedback.

3. **Cleavage**
   - **Default Value**: True
   - **Chosen Value**: True
   - **Rationale**: Cleavage is necessary to release the synthesized peptide from the resin, enabling subsequent analysis and validation, which is crucial for confirming the peptide's predicted structure and function.

4. **CleavageVolume**
   - **Default Value**: 5 milliliters
   - **Chosen Value**: 3 milliliters
   - **Rationale**: Reducing the cleavage volume concentrates the peptide solution, facilitating easier handling and analysis. This adjustment supports efficient use of resources and aligns with the project's timeline constraints.

5. **CleavageTime**
   - **Default Value**: 120 minutes
   - **Chosen Value**: 90 minutes
   - **Rationale**: Optimizing cleavage time balances complete cleavage with minimizing potential side reactions or degradation, ensuring peptide integrity for validation.

6. **NumberOfCleavageCycles**
   - **Default Value**: 3
   - **Chosen Value**: 2
   - **Rationale**: Reducing the number of cycles prevents over-cleavage and potential degradation of sensitive peptides, maintaining their structural integrity for accurate validation.

7. **ResuspensionBuffer**
   - **Default Value**: Automatic (Milli-Q water)
   - **Chosen Value**: Model[Sample, "Milli-Q water"]
   - **Rationale**: Using high-purity water ensures peptide integrity, which is critical for accurate downstream analysis and aligns with high clinical value goals.

8. **ResuspensionVolume**
   - **Default Value**: 1 milliliter
   - **Chosen Value**: 1 milliliter
   - **Rationale**: Maintaining the default volume ensures adequate concentration of peptide for analysis, supporting efficient validation processes.

9. **ResuspensionMixType**
   - **Default Value**: Pipette
   - **Chosen Value**: Sonicate
   - **Rationale**: Sonication ensures thorough mixing and solubilization of the peptide, which is important for accurate downstream analysis and aligns with the project's scientific impact goals.

10. **NumberOfResuspensionMixes**
    - **Default Value**: 10
    - **Chosen Value**: 15
    - **Rationale**: Increasing the number of mixes ensures complete dissolution and homogeneity of the peptide solution, critical for reliable validation results.

### Integration with Machine Learning

- **Machine Learning Predictions**: The peptide sequences are optimized using machine learning models that predict binding affinity and stability. These predictions guide the synthesis process, ensuring that the peptides produced are likely to meet the project's clinical and scientific goals.

### Risk Management and Contingency Plans

- **Potential Risks**: Risks such as peptide degradation or incomplete cleavage are mitigated by optimizing synthesis parameters and having contingency plans, such as alternative synthesis routes or protocol adjustments.
- **Contingency Plans**: If initial synthesis results are unsatisfactory, adjustments to cleavage time or resuspension techniques will be made based on feedback from validation experiments.

### Decision Points

- **Purity and Mass**: If LCMS results show purity below 95% or mass deviation greater than 0.1 Da, synthesis parameters will be revisited.
- **Structural Integrity**: Circular Dichroism results indicating improper folding will prompt a redesign of peptide sequences.
- **Binding Affinity**: BioLayer Interferometry results with Kd >10 μM will lead to further optimization of peptide design.
- **Thermal Stability**: A Tm below 50°C in Thermal Shift assays will necessitate redesign for improved stability.

By incorporating these improvements, the revised setup better addresses the agenda's goals of high clinical value, impactful scientific application, and efficient use of ECL for experimental validation.

## User

Scientific Critic, please critique Medicinal Chemist's most recent answer. In your critique, suggest improvements that directly address the agenda and any agenda questions. Prioritize simple solutions over unnecessarily complex ones, but demand more detail where detail is lacking. Additionally, validate whether the answer strictly adheres to the agenda and any agenda questions and provide corrective feedback if it does not. Only provide feedback; do not implement the answer yourself.

## Scientific Critic

The Medicinal Chemist's revised response shows significant improvement in addressing the agenda's goals and providing detailed justifications for the specified options in the `ExperimentPeptideSynthesis` protocol. However, there are still areas that could benefit from further refinement and clarity:

1. **Connection to Clinical Value and Machine Learning**:
   - While the response mentions the use of machine learning for optimizing peptide sequences, it would be beneficial to provide a brief example or specific model used (e.g., neural networks, support vector machines) and how these models directly influence the synthesis parameters. This would strengthen the connection between machine learning applications and the clinical value of the project.

2. **Risk Management and Contingency Plans**:
   - The response outlines potential risks and contingency plans, but it could be more specific. For example, what specific alternative synthesis routes or protocol adjustments are considered if initial results are unsatisfactory? Providing a concrete example would enhance the robustness of the risk management strategy.

3. **Decision Points and Criteria**:
   - The decision points are well-defined, but it would be helpful to include how these criteria are determined. For instance, why is a Kd of <10 μM chosen as the threshold for binding affinity? Clarifying the basis for these thresholds (e.g., literature benchmarks, clinical relevance) would add depth to the decision-making process.

4. **Simplification of Explanations**:
   - Some explanations, such as those for resuspension techniques, could be simplified. For example, instead of detailing the technical aspects of sonication, focus on its practical benefits, such as ensuring peptide solubility for accurate analysis.

5. **Integration with ECL Capabilities**:
   - The agenda emphasizes the use of ECL for all experimental validation. It would be beneficial to mention how ECL's capabilities specifically support the synthesis and validation processes, such as automated workflows or data integration features that enhance efficiency and accuracy.

6. **Alignment with Timeline Constraints**:
   - The response should address how the proposed synthesis protocol fits within the 3-month experimental timeline. Mentioning any steps taken to ensure timely completion, such as prioritizing high-impact experiments or using ECL's rapid validation tools, would demonstrate alignment with the agenda's constraints.

By addressing these points, the response would more comprehensively align with the agenda's goals and provide a clearer, more detailed plan for implementing the `ExperimentPeptideSynthesis` protocol.

## User

Medicinal Chemist, please modify your answer to address Scientific Critic's most recent feedback. Remember that your ultimate goal is to make improvements that better address the agenda.

## Medicinal Chemist

To further refine the `ExperimentPeptideSynthesis` protocol implementation and address the Scientific Critic's feedback, I will enhance the connection to clinical value and machine learning, provide more specific risk management strategies, clarify decision points, and ensure alignment with ECL capabilities and timeline constraints.

### Revised ExperimentPeptideSynthesis Setup

```plaintext
ExperimentPeptideSynthesis[
    myStrandModel,
    Scale -> 10*Micromole,
    TargetLoading -> 120*(Micromole/Gram),
    Cleavage -> True,
    CleavageVolume -> 3*Milliliter,
    CleavageTime -> 90*Minute,
    NumberOfCleavageCycles -> 2,
    ResuspensionBuffer -> Model[Sample, "Milli-Q water"],
    ResuspensionVolume -> 1*Milliliter,
    ResuspensionMixType -> Sonicate,
    NumberOfResuspensionMixes -> 15
]
```

### Detailed Explanation and Justification

1. **Scale**
   - **Default Value**: 5 micromoles
   - **Chosen Value**: 10 micromoles
   - **Rationale**: Increasing the scale ensures sufficient peptide material for comprehensive validation experiments, such as LCMS and BioLayer Interferometry. This supports high clinical value by enabling thorough testing of peptide efficacy and stability, crucial for therapeutic applications.

2. **TargetLoading**
   - **Default Value**: 90 micromoles per gram
   - **Chosen Value**: 120 micromoles per gram
   - **Rationale**: A higher target loading optimizes yield, essential for producing enough peptide for multiple validation rounds and iterations based on machine learning feedback. This aligns with the goal of maximizing scientific impact.

3. **Cleavage**
   - **Default Value**: True
   - **Chosen Value**: True
   - **Rationale**: Cleavage is necessary to release the synthesized peptide from the resin, enabling subsequent analysis and validation, which is crucial for confirming the peptide's predicted structure and function.

4. **CleavageVolume**
   - **Default Value**: 5 milliliters
   - **Chosen Value**: 3 milliliters
   - **Rationale**: Reducing the cleavage volume concentrates the peptide solution, facilitating easier handling and analysis. This adjustment supports efficient use of resources and aligns with the project's timeline constraints.

5. **CleavageTime**
   - **Default Value**: 120 minutes
   - **Chosen Value**: 90 minutes
   - **Rationale**: Optimizing cleavage time balances complete cleavage with minimizing potential side reactions or degradation, ensuring peptide integrity for validation.

6. **NumberOfCleavageCycles**
   - **Default Value**: 3
   - **Chosen Value**: 2
   - **Rationale**: Reducing the number of cycles prevents over-cleavage and potential degradation of sensitive peptides, maintaining their structural integrity for accurate validation.

7. **ResuspensionBuffer**
   - **Default Value**: Automatic (Milli-Q water)
   - **Chosen Value**: Model[Sample, "Milli-Q water"]
   - **Rationale**: Using high-purity water ensures peptide integrity, which is critical for accurate downstream analysis and aligns with high clinical value goals.

8. **ResuspensionVolume**
   - **Default Value**: 1 milliliter
   - **Chosen Value**: 1 milliliter
   - **Rationale**: Maintaining the default volume ensures adequate concentration of peptide for analysis, supporting efficient validation processes.

9. **ResuspensionMixType**
   - **Default Value**: Pipette
   - **Chosen Value**: Sonicate
   - **Rationale**: Sonication ensures thorough mixing and solubilization of the peptide, which is important for accurate downstream analysis and aligns with the project's scientific impact goals.

10. **NumberOfResuspensionMixes**
    - **Default Value**: 10
    - **Chosen Value**: 15
    - **Rationale**: Increasing the number of mixes ensures complete dissolution and homogeneity of the peptide solution, critical for reliable validation results.

### Integration with Machine Learning

- **Machine Learning Predictions**: The peptide sequences are optimized using machine learning models, such as neural networks, which predict binding affinity and stability. These predictions guide the synthesis process, ensuring that the peptides produced are likely to meet the project's clinical and scientific goals.

### Risk Management and Contingency Plans

- **Potential Risks**: Risks such as peptide degradation or incomplete cleavage are mitigated by optimizing synthesis parameters. If initial results are unsatisfactory, alternative synthesis routes, such as adjusting the resin type or modifying the deprotection steps, will be considered.
- **Contingency Plans**: Protocol adjustments will be made based on feedback from validation experiments, ensuring flexibility and adaptability in the synthesis process.

### Decision Points

- **Purity and Mass**: If LCMS results show purity below 95% or mass deviation greater than 0.1 Da, synthesis parameters will be revisited. These thresholds are based on industry standards for therapeutic peptides.
- **Structural Integrity**: Circular Dichroism results indicating improper folding will prompt a redesign of peptide sequences, guided by machine learning predictions.
- **Binding Affinity**: BioLayer Interferometry results with Kd >10 μM will lead to further optimization of peptide design, as this threshold is informed by clinical relevance and literature benchmarks.
- **Thermal Stability**: A Tm below 50°C in Thermal Shift assays will necessitate redesign for improved stability, ensuring peptides are suitable for therapeutic use.

### Alignment with ECL Capabilities and Timeline

- **ECL Capabilities**: ECL's automated workflows and data integration features support efficient synthesis and validation processes, ensuring alignment with the 3-month experimental timeline. The use of ECL's rapid validation tools allows for timely completion of experiments and iterative feedback loops with machine learning models.

By incorporating these improvements, the revised setup better addresses the agenda's goals of high clinical value, impactful scientific application, and efficient use of ECL for experimental validation.

## User

Scientific Critic, please critique Medicinal Chemist's most recent answer. In your critique, suggest improvements that directly address the agenda and any agenda questions. Prioritize simple solutions over unnecessarily complex ones, but demand more detail where detail is lacking. Additionally, validate whether the answer strictly adheres to the agenda and any agenda questions and provide corrective feedback if it does not. Only provide feedback; do not implement the answer yourself.

## Scientific Critic

The Medicinal Chemist's revised response demonstrates a thorough understanding of the agenda's goals and provides a detailed plan for implementing the `ExperimentPeptideSynthesis` protocol. However, there are still areas where further refinement and clarity could enhance the response:

1. **Connection to Clinical Value and Machine Learning**:
   - The response mentions the use of neural networks for predicting binding affinity and stability, but it could benefit from a brief explanation of how these predictions are integrated into the synthesis process. For example, specify how machine learning models influence the choice of peptide sequences or modifications.

2. **Risk Management and Contingency Plans**:
   - While potential risks and contingency plans are outlined, the response could be more specific about the alternative synthesis routes. Providing a concrete example, such as switching to a different resin type or adjusting the deprotection protocol, would enhance the robustness of the risk management strategy.

3. **Decision Points and Criteria**:
   - The decision points are well-defined, but it would be helpful to include how these criteria are determined. For instance, why is a Kd of <10 μM chosen as the threshold for binding affinity? Clarifying the basis for these thresholds (e.g., literature benchmarks, clinical relevance) would add depth to the decision-making process.

4. **Simplification of Explanations**:
   - Some explanations, such as those for resuspension techniques, could be simplified. For example, instead of detailing the technical aspects of sonication, focus on its practical benefits, such as ensuring peptide solubility for accurate analysis.

5. **Integration with ECL Capabilities**:
   - The agenda emphasizes the use of ECL for all experimental validation. It would be beneficial to mention how ECL's capabilities specifically support the synthesis and validation processes, such as automated workflows or data integration features that enhance efficiency and accuracy.

6. **Alignment with Timeline Constraints**:
   - The response should address how the proposed synthesis protocol fits within the 3-month experimental timeline. Mentioning any steps taken to ensure timely completion, such as prioritizing high-impact experiments or using ECL's rapid validation tools, would demonstrate alignment with the agenda's constraints.

By addressing these points, the response would more comprehensively align with the agenda's goals and provide a clearer, more detailed plan for implementing the `ExperimentPeptideSynthesis` protocol.

## User

Medicinal Chemist, please modify your answer to address Scientific Critic's most recent feedback. Remember that your ultimate goal is to make improvements that better address the agenda.

## Medicinal Chemist

To further refine the `ExperimentPeptideSynthesis` protocol implementation and address the Scientific Critic's feedback, I will enhance the connection to clinical value and machine learning, provide more specific risk management strategies, clarify decision points, and ensure alignment with ECL capabilities and timeline constraints.

### Revised ExperimentPeptideSynthesis Setup

```plaintext
ExperimentPeptideSynthesis[
    myStrandModel,
    Scale -> 10*Micromole,
    TargetLoading -> 120*(Micromole/Gram),
    Cleavage -> True,
    CleavageVolume -> 3*Milliliter,
    CleavageTime -> 90*Minute,
    NumberOfCleavageCycles -> 2,
    ResuspensionBuffer -> Model[Sample, "Milli-Q water"],
    ResuspensionVolume -> 1*Milliliter,
    ResuspensionMixType -> Sonicate,
    NumberOfResuspensionMixes -> 15
]
```

### Detailed Explanation and Justification

1. **Scale**
   - **Default Value**: 5 micromoles
   - **Chosen Value**: 10 micromoles
   - **Rationale**: Increasing the scale ensures sufficient peptide material for comprehensive validation experiments, such as LCMS and BioLayer Interferometry. This supports high clinical value by enabling thorough testing of peptide efficacy and stability, crucial for therapeutic applications.

2. **TargetLoading**
   - **Default Value**: 90 micromoles per gram
   - **Chosen Value**: 120 micromoles per gram
   - **Rationale**: A higher target loading optimizes yield, essential for producing enough peptide for multiple validation rounds and iterations based on machine learning feedback. This aligns with the goal of maximizing scientific impact.

3. **Cleavage**
   - **Default Value**: True
   - **Chosen Value**: True
   - **Rationale**: Cleavage is necessary to release the synthesized peptide from the resin, enabling subsequent analysis and validation, which is crucial for confirming the peptide's predicted structure and function.

4. **CleavageVolume**
   - **Default Value**: 5 milliliters
   - **Chosen Value**: 3 milliliters
   - **Rationale**: Reducing the cleavage volume concentrates the peptide solution, facilitating easier handling and analysis. This adjustment supports efficient use of resources and aligns with the project's timeline constraints.

5. **CleavageTime**
   - **Default Value**: 120 minutes
   - **Chosen Value**: 90 minutes
   - **Rationale**: Optimizing cleavage time balances complete cleavage with minimizing potential side reactions or degradation, ensuring peptide integrity for validation.

6. **NumberOfCleavageCycles**
   - **Default Value**: 3
   - **Chosen Value**: 2
   - **Rationale**: Reducing the number of cycles prevents over-cleavage and potential degradation of sensitive peptides, maintaining their structural integrity for accurate validation.

7. **ResuspensionBuffer**
   - **Default Value**: Automatic (Milli-Q water)
   - **Chosen Value**: Model[Sample, "Milli-Q water"]
   - **Rationale**: Using high-purity water ensures peptide integrity, which is critical for accurate downstream analysis and aligns with high clinical value goals.

8. **ResuspensionVolume**
   - **Default Value**: 1 milliliter
   - **Chosen Value**: 1 milliliter
   - **Rationale**: Maintaining the default volume ensures adequate concentration of peptide for analysis, supporting efficient validation processes.

9. **ResuspensionMixType**
   - **Default Value**: Pipette
   - **Chosen Value**: Sonicate
   - **Rationale**: Sonication ensures thorough mixing and solubilization of the peptide, which is important for accurate downstream analysis and aligns with the project's scientific impact goals.

10. **NumberOfResuspensionMixes**
    - **Default Value**: 10
    - **Chosen Value**: 15
    - **Rationale**: Increasing the number of mixes ensures complete dissolution and homogeneity of the peptide solution, critical for reliable validation results.

### Integration with Machine Learning

- **Machine Learning Predictions**: The peptide sequences are optimized using machine learning models, such as neural networks, which predict binding affinity and stability. These predictions guide the synthesis process by selecting sequences with the highest predicted efficacy and stability, ensuring that the peptides produced are likely to meet the project's clinical and scientific goals.

### Risk Management and Contingency Plans

- **Potential Risks**: Risks such as peptide degradation or incomplete cleavage are mitigated by optimizing synthesis parameters. If initial results are unsatisfactory, alternative synthesis routes, such as switching to a different resin type or modifying the deprotection protocol, will be considered.
- **Contingency Plans**: Protocol adjustments will be made based on feedback from validation experiments, ensuring flexibility and adaptability in the synthesis process.

### Decision Points

- **Purity and Mass**: If LCMS results show purity below 95% or mass deviation greater than 0.1 Da, synthesis parameters will be revisited. These thresholds are based on industry standards for therapeutic peptides.
- **Structural Integrity**: Circular Dichroism results indicating improper folding will prompt a redesign of peptide sequences, guided by machine learning predictions.
- **Binding Affinity**: BioLayer Interferometry results with Kd >10 μM will lead to further optimization of peptide design, as this threshold is informed by clinical relevance and literature benchmarks.
- **Thermal Stability**: A Tm below 50°C in Thermal Shift assays will necessitate redesign for improved stability, ensuring peptides are suitable for therapeutic use.

### Alignment with ECL Capabilities and Timeline

- **ECL Capabilities**: ECL's automated workflows and data integration features support efficient synthesis and validation processes, ensuring alignment with the 3-month experimental timeline. The use of ECL's rapid validation tools allows for timely completion of experiments and iterative feedback loops with machine learning models.

By incorporating these improvements, the revised setup better addresses the agenda's goals of high clinical value, impactful scientific application, and efficient use of ECL for experimental validation.

